



Healthcare Improvement Scotland | SMC  
Advice on new medicines

# A Partnership Approach to Patient and Public Involvement in HTA Scotland

Miranda Pierre, Health Services Researcher, Scottish Medicines Consortium



1


## What we do




Ensuring that medicines offering good value are accepted quickly so that patients can benefit

- Assess all new medicines / indications / formulations - 'once for Scotland'
- Pharmaceutical company submission on health benefits and justification of price relative to current clinical practice
- Two stage process – New Drugs Committee the SMC Committee

2



3



4

## The role of Public Partners

### SMC Committee Member (3 Public Partners on SMC Committee)

- As a member of the public, they use their judgement on the value of a new medicine to NHSScotland as a full voting member of the SMC Committee.
- Read evidence provided by manufacturer on clinical and cost effectiveness of a new medicine, along with analysis by SMC team, written input from clinical experts and patient group submissions.
- Attend 12 monthly SMC committee meetings, sharing their views clearly and sensitively from a public perspective, and asking challenging questions, when required.

5

## The role of patient and carer representatives

Help SMC committee members fully understand the impact of a new medicine to patients and carers



6

## How we encourage and support engagement

### Strengthened engagement

- Reach out to condition specific patient groups encouraging participation
- Develop positive partnership relationships with patient groups
- Public Involvement Network (PIN) Advisory Group

### Information provision

- Background info from manufacturer (SIP)
- Training, written guidance, short films
- Embargoed early release of SMC decisions

### Ongoing support

- Ongoing 1:1 support before, during and after participation (MSTeams, email, telephone)

Submitting Patient Group Partners' view of information and support received throughout participation in SMC assessment

**100% Good/Very Good**

7

## Written submission process

- Proactive approach
- One off registration for Patient Group Partners
- Regularly updated Patient Group Submission Form
- Guidance booklet for patient group submissions
- Summary Information for Submitting Patient Groups form
- 1:1 support from SMC Public Involvement Advisor – including review of draft submission
- Embargoed early release of decision to submitting patient groups



8

## Education provision

- Patient Group Partner Events
- Presenting at external events run by Patient Group Partners
- Virtual Education and Update Sessions
- Short educational films on website



9

## Public Involvement Network (PIN) Advisory Group

### Membership:



The National Alliance for people with rare diseases & all who support them



*3 Patient Group Partners, 3 Public Partners, ADTC Collaborative Member, SMC Committee Member (clinical expert), SMC Executive Members*

- Collaborative agenda setting
- Recommendations to SMC Executive
- Direct influence on SMC processes and strategy
- Continuous development and strengthening of patient and public involvement in HTA

10

## Key figures (2022)

- 164** Patient Groups actively engaged with
- 178** Registered SMC Patient Group Partners
- 83** Patient Group Submissions to SMC
- 51** Patient Group Representatives supported to participate in PACE
- 54** Patient Group Representatives supported to participate at SMC Committee Meetings

11

## Impact – satisfaction of Patient Group Partners

Submitting Patient Group Partners' view of information and support received throughout participation in SMC assessment

**100% Good/Very Good**

(0% Average or Poor, n=20)

### Support Received

*"The support we received throughout the submission process was first class, providing useful tips and feedback and helped in ensuring our submission was as impactful as possible. Thank you!"*

Niall Sommerville, The MS Society

### Participating at SMC Committee Meeting

*"Everyone was very friendly, everything was made very clear, it was obvious that everyone in the room had a good level of understanding about the treatment they were voting on and it was a very inclusive environment."* Tanya Collin-Histed, Gauchers Association

12

## Impact – satisfaction of SMC Committee Members

*“Enabling patient interest groups and the public to contribute to a discussion on the likely impact of a new medicine has enriched our deliberations and consequently the decisions committee members are able to make.”*

**Chairman – SMC**

*“SMC decision making is a complex and collaborative process which benefits from the engagement of all who can bring their specialist knowledge. Enhancing the involvement of patient group representatives provides a valuable additional voice to support the Committee.”*

**SMC Committee Member**



13

## Thank you and Questions?



[www.scottishmedicines.org.uk](http://www.scottishmedicines.org.uk)

14